Moreover, an association between gBRCA1/2 and early resistance to CDK4/6i in luminal tumours is being increasingly recognised, where HRD genomic features may also be enriched after progression to CDK4/6i.210, 211, 212, 213, 214, 215. Here, CDK4 is linked to neoplasm.